Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of GNR-139 in Comparison With Eylea® (114.3 mg/mL) in Patients With nAMD

NCT07844148 is registered in ClinicalTrials.gov with AO GENERIUM as lead sponsor.

NCT NCT07844148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07844148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of GNR-139 in Comparison With Eylea® (114.3 mg/mL) in Patients With nAMD
Lead sponsor
AO GENERIUM
Phase
Phase 3
Overall status
Recruiting
Start date
July 22, 2026
Completion date
May 31, 2028
Enrollment
180 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

namd